PMID- 15471364
OWN - NLM
STAT- MEDLINE
DCOM- 20050126
LR  - 20170214
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 10
IP  - 5
DP  - 2004 Oct
TI  - Regulation of differentiation and functional properties of monocytes and 
      monocyte-derived dendritic cells by interferon beta in multiple sclerosis.
PG  - 499-506
AB  - Interferon beta (IFN beta) has complex immune regulatory properties that 
      contribute to its treatment effect on multiple sclerosis (MS). In this study, we 
      investigated the role of IFN beta in differentiation and functional properties of 
      monocytes and monocyte-derived dendritic cells that are critical to the 
      inflammatory process in MS. The results revealed that IFN beta inhibited 
      intracellular production of interleukin (IL)-1b (P<0.01) in both monocytes 
      exposed to in vitro treatment of IFN beta and monocytes analysed ex vivo from MS 
      patients treated with IFN beta. IFN beta was shown to modulate differentiation of 
      monocytes into dendritic cells in the presence of IL-4 and GM-CSF, which resulted 
      in a delayed differentiation process. Furthermore, it characteristically altered 
      the phenotypic features of differentiated dendritic cells by inhibiting the 
      expression of CD1a, CD11b, CD11c, CD123 and CD209 while upregulating 
      costimulatory molecules, such as CD86. The selective regulatory properties of IFN 
      beta appeared to render the function of differentiated dendritic cells to produce 
      an increased amount (P<0.01) while their ability to secrete proinflammatory IL-12 
      and TGF beta was significantly reduced. The observed collective effects of IFN 
      beta seemed to correlate with Th2 immune deviation. The study has provided new 
      insights into the regulatory mechanisms of IFN beta in the treatment of MS.
FAU - Zang, Ying C Q
AU  - Zang YC
AD  - Multiple Sclerosis Research Unit, Department of Neurology and Baylor Multiple 
      Sclerosis Center, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Skinner, Sheri M
AU  - Skinner SM
FAU - Robinson, Rachel R
AU  - Robinson RR
FAU - Li, Sufang
AU  - Li S
FAU - Rivera, Victor M
AU  - Rivera VM
FAU - Hutton, George J
AU  - Hutton GJ
FAU - Zhang, Jingwu Z
AU  - Zhang JZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Interleukin-1)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 77238-31-4 (Interferon-beta)
RN  - XRO4566Q4R (Interferon beta-1a)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Adult
MH  - Cell Differentiation/drug effects/immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*drug effects/metabolism
MH  - Humans
MH  - Immunophenotyping
MH  - Interferon beta-1a
MH  - Interferon-beta/*administration & dosage
MH  - Interleukin-1/metabolism
MH  - Middle Aged
MH  - Monocytes/cytology/*drug effects/metabolism
MH  - Multiple Sclerosis, Chronic Progressive/*drug therapy/immunology
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2004/10/09 09:00
MHDA- 2005/01/27 09:00
CRDT- 2004/10/09 09:00
PHST- 2004/10/09 09:00 [pubmed]
PHST- 2005/01/27 09:00 [medline]
PHST- 2004/10/09 09:00 [entrez]
AID - 10.1191/1352458504ms1081oa [doi]
PST - ppublish
SO  - Mult Scler. 2004 Oct;10(5):499-506. doi: 10.1191/1352458504ms1081oa.